Curasight AS (XSAT:CURAS) ROCE %: -492.28% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:CURAS Curasight AS XSAT:CURAS
24 GF Score
Price kr16.75
! 2 Warning Signs
View Full Analysis

What is Curasight AS ROCE %?

Curasight AS XSAT:CURAS -1.47% 24 ROCE % is -492.28% as of Mar. 2026. GuruFocus rates XSAT:CURAS with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Curasight AS's annualized ROCE % for the quarter that ended in Mar. 2026 was -492.28%.

Curasight AS  (XSAT:CURAS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Curasight AS ROCE % Related Terms

Curasight AS ROCE % Historical Data

* Premium members only.

The historical data trend for Curasight AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curasight AS ROCE % Chart

Curasight AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -16.65 -28.42 -74.69 -205.16 -433.19

Curasight AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -486.12 -463.54 -226.82 -365.15 -492.28
XSAT:CURAS
24GF Score
Curasight AS XSAT:CURAS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curasight AS ROCE % Calculation

Curasight AS's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-55.55/( ( (23.688 - 15.977) + (50.055 - 32.119) )/ 2 )
=-55.55/( (7.711+17.936)/ 2 )
=-55.55/12.8235
=-433.19 %

Curasight AS's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-61.112/( ( (50.055 - 32.119) + (36.246 - 29.354) )/ 2 )
=-61.112/( ( 17.936 + 6.892 )/ 2 )
=-61.112/12.414
=-492.28 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -492.28% mean?
Curasight AS (XSAT:CURAS) has a ROCE % of -492.28% as of Mar. 2026.
Is Curasight AS's ROCE % too high?
Curasight AS's current ROCE % is -492.28%. Overall, Curasight AS has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Curasight AS's ROCE % compare to VRTX and REGN?
Curasight AS's ROCE % of -492.28% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Curasight AS's current ROCE % is -492.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curasight AS stock overvalued right now?
Curasight AS (XSAT:CURAS) has a current ROCE % of -492.28%. The current ROCE % is -492.28%. Curasight AS's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Curasight AS (XSAT:CURAS), the current ROCE % is -492.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curasight AS Business Description

Other Exchanges CUS:Germany
Address Ole Maaloes Vej 3, Kobenhavn N, Kobenhavn, DNK, DK-2200
Curasight AS is a clinical-stage radiopharmaceutical company based in Copenhagen, Denmark, developing uTREAT, a first-in-class uPAR-targeted radioligand therapy (RLT) platform designed to treat aggressive solid tumors. The Company is focused on advancing its diagnostic and therapeutic platforms through key clinical milestones.
24GF Score

Get the complete analysis for XSAT:CURAS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr16.75
Price